Evelo Biosciences Inc

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed – – Clear path to registration trials for EDP1815 in psoriasis base d on recently completed interactions with F DA, EMA and MHRA – – Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 – – Optimizing operations and reducing workforce to focus resources on strategic priorities – – CEO Simba Gill, Ph.D., will continue to lead the organization, halting search for successor – – Management to host conference call today at 8:30 a.m. ET –

Evelo Biosciences Provides Clinical and Business Updates

Horizon Technology Finance

- Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN - - HRZN Grows Loan Portfolio by $262 Million in 2022 - - Horizon Platform Ends 2022 with Committed Backlog of $255 Million, Including $220 Million in HRZN Commitments -    FARMINGTON, Conn. , Jan. 11, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the fourth quarter ended December 31, 2022 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM"), its investment adviser.

Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement with Horizon Technology Finance Corporation (Horizon) (Nasdaq: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services and sustainability industries. The $45 million term loan, which provides for three years of interest-only payments followed by a two-year amortization period, replaces the Company's existing senior secured debt which would have begun amortizing in March 2023.

Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt

CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines, today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday, November 30th, including discussion of how this science enables the broad inflammation resolving potential of SINTAX medicines.

Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology

- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 -

Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 7:25 a.m. GMT.

Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Evelo Biosciences, Inc. (NASDAQ: EVLO). If you are a shareholder of Evelo Biosciences, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/evelo-biosciences-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company's lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis. The data were presented in a poster at the 2022 EADV Congress in Milan, Italy.

Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that on September 1, 2022, Marella Thorell commenced her services as Evelo's Chief Financial Officer. In connection with the commencement of Ms. Thorell's employment, the Company issued to Ms. Thorell an option to purchase 440,000 shares of the Company's common stock with a per share exercise price of $2.29, the closing trading price of the Company's common stock on the Nasdaq Global Select Market on September 1, 2022. The stock option was granted pursuant to the Company's 2021 Employment Inducement Award Plan and was approved by the Company's Board of Directors. The stock option vests (subject to Ms. Thorell's continued service to the Company through the applicable vesting dates) 25% on September 1, 2023 and the remaining 75% in 36 substantially equal monthly installments over the three years thereafter and has a ten-year term. The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to Ms. Thorell's entering into employment with the Company.

Evelo Biosciences Announces Grant of Inducement Award

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Health Care Conference on Tuesday, September 13th, 2022 at 12:20 p.m. ET.

Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference

Evelo Biosciences, Inc. (NASDAQ:EVLO ) Q2 2022 Earnings Conference Call August 11, 2022 7:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Ara Darzi - Chairman Conference Call Participants Chris Howerton - Jefferies Joseph Thome - Cowen Vikram Purohit - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Operator Good morning and welcome to the Evelo Biosciences Conference Call to discuss its Second Quarter 2022 Business Highlights. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2022 Results - Earnings Call Transcript

– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search –

Evelo Biosciences Announces Succession Plan

– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase 2 data for EDP2939 in psoriasis expected in 2H 2023 –– Management will host conference call at 7:30 a.m. ET –

Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 7:30 a.m. ET on Thursday, August 11, 2022, to report its second quarter 2022 financial results.

Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the appointment of Marella Thorell as Chief Financial Officer (CFO), effective September 1, 2022.

Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million. The offering is being led by Evelo's founder, Flagship Pioneering, with participation from other new and existing investors.

Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be “As of March 31, 2022, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of December 31, 2021,” not December 31, 2021 and March 31, 2021. The corrected release follows:

CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022.

Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors.

Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors

–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release capsule cohort to be added to on-going Phase 2 trial of EDP1815 in atopic dermatitis; data expected 1H 2023–

Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) --  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors.

Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held March 25-29 in Boston, Massachusetts.

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting

In the Q4 earnings release, Evelo Biosciences Inc (NASDAQ: EVLO) shared results from an ongoing Phase 1 single-center trial in healthy volunteers that showed that a capsule with an improved release profile could deliver EDP1815 higher up in the small intestine.  88% (15 out of 17).

Evelo Biosciences Shares Gain After Positive Data On Faster Release EDP1815 Capsule, Q4 Earnings

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q4 2021 Results - Earnings Call Transcript

–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ––Positive data reported on faster release capsule––Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout––Management to host conference call at 8:30 a.m. ET–

News for Evelo Biosciences Inc Stock (EVLO)